Key Details
Price
$59.45PE Ratio
24.67Annual ROE
13.22%Beta
0.57Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
Feb 6, 2025Recent annual earnings:
May 9, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Dec 3, 2012Analyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
Although the revenue and EPS for Haemonetics (HAE) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Haemonetics (HAE) came out with quarterly earnings of $1.19 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $1.04 per share a year ago.
Financial release accessible online BOSTON , Feb. 6, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its third quarter fiscal year 2025, which ended December 28, 2024, are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m.
Haemonetics completes the sale of whole blood assets to GVS, S.p.A.
Investors interested in Medical - Products stocks are likely familiar with Haemonetics (HAE) and Abbott (ABT). But which of these two companies is the best option for those looking for undervalued stocks?
BOSTON , Jan. 14, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, today announced that it has completed the previously announced sale of its whole blood assets to GVS, S.p.A ("GVS"), one of the world's leading manufacturers of filter solutions for applications in the healthcare and life sciences sectors. In connection with the closing of this transaction, GVS has acquired Haemonetics' portfolio of proprietary whole blood collection, processing and filtration solutions, along with Haemonetics' manufacturing facility in Covina, California where certain of these products are produced, and related equipment and assets located at Haemonetics' manufacturing facility in Tijuana, Mexico.
BOSTON , Jan. 8, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish third quarter fiscal year 2025 financial results at 6:00 am ET on Thursday, February 6, 2025. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on February 6, 2025.
BOSTON , Jan. 6, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 14, 2025 at 5:15 pm Pacific Time.
Investors interested in stocks from the Medical - Products sector have probably already heard of Haemonetics (HAE) and Abbott (ABT). But which of these two stocks offers value investors a better bang for their buck right now?
Strong prospects for the Plasma franchise and favorable solvency bode well for Haemonetics.
FAQ
- What is the ticker symbol for Haemonetics?
- Does Haemonetics pay dividends?
- What sector is Haemonetics in?
- What industry is Haemonetics in?
- What country is Haemonetics based in?
- When did Haemonetics go public?
- Is Haemonetics in the S&P 500?
- Is Haemonetics in the NASDAQ 100?
- Is Haemonetics in the Dow Jones?
- When was Haemonetics's last earnings report?
- When does Haemonetics report earnings?
- Should I buy Haemonetics stock now?